H-237 Citrate | 15624-34-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: H-237 Citrate
• 英文别名: N,N-diethyl-2-[4-[1-(4-methoxyphenyl)propan-2-yl]phenoxy]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
• CAS: 15624-34-7
• 化学式: C28H39NO9
• 分子量: 533.6
• InChiKey: JXWBFODZYRPZEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.51
• 重原子数：
  38
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  154
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• Drug regulated transgene expression
  申请人：Seattle Children's Hospital

  公开号：US10266592B2

  公开（公告）日：2019-04-23

  The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

  本发明提供了核酸、载体、宿主细胞、方法和组合物，以赋予和/或增强由细胞免疫疗法介导的免疫应答，例如通过收养性转移CD8+中心记忆T细胞或中心记忆T细胞与CD4+T细胞的组合，这些细胞经过遗传修饰，在可诱导启动子的控制下表达嵌合受体。在某些替代方案中，转基因宿主细胞包括核酸，该核酸包含编码嵌合抗原受体的多核苷酸，嵌合抗原受体包含配体结合域、包含间隔区的多核苷酸、包含跨膜域的多核苷酸和包含细胞内信号传导域的多核苷酸，受药物诱导启动子控制。通过控制嵌合受体的表达，可以根据患者的状态开启或关闭表达。还描述了用该方法生产的药物制剂和使用方法。
• Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment
  申请人：Seattle Children's Hospital

  公开号：US10919950B2

  公开（公告）日：2021-02-16

  The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.

  本申请涉及融合蛋白、表达融合蛋白的嵌合抗原携带细胞和包含表达融合蛋白的嵌合抗原携带细胞的组合物。本申请还涉及使用融合蛋白、细胞和组合物调节免疫反应的方法。
• Bispecific CAR T-cells for solid tumor targeting
  申请人：Seattle Children's Hospital

  公开号：US11123369B2

  公开（公告）日：2021-09-21

  Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.

  本文所公开的方法是设计一种表达嵌合抗原受体的双特异性 T 细胞，用于促进效应细胞和第二种嵌合抗原受体或 TcR 的体内扩增和活化，第二种嵌合抗原受体或 TcR 对肿瘤上的配体具有特异性。还提供了向有需要的受试者施用携带双特异性嵌合抗原受体细胞的方法。
• DRUG RELATED TRANSGENE EXPRESSION
  申请人：Seattle Children's Hospital, dba Seattle Children's Research Institute

  公开号：EP3129399A1

  公开（公告）日：2017-02-15
• BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING
  申请人：Seattle Children's Hospital, dba Seattle Children's Research Institute

  公开号：EP3331920A1

  公开（公告）日：2018-06-13